Press release [1]: > CureVac estimates that the earliest potential approval of [first-generation vaccine] would come in the second quarter of 2022. By this tim

Press release [1]: > CureVac estimates that the earliest potential approval of [first-generation vaccine] would come in the second quarter of 2022. By this time, the companies expect the candidates from the second-generation vaccine program to have progressed to late-stage clinical development. What's the goal of having a COVID vaccine market ready in the third/fourth quarter of 2022? And how will they achieve it? Will it be authorized under an Emergency Use Authorization? Do they anticipate that the circumstances justifying EUA's will continue? [1] https://www.curevac.com/en/2021/10/12/curevac-to-shift-focus-of-covid-19-vaccine-development-to-second-generation-mrna-technology/ https://www.curevac.com/en/2021/10/12/curevac-to-shift-focus...